Preferential transcription of the mutated allele in NPM1 mutated acute myeloid leukaemia

Bailey, G. D.; Doolan, L.; Baskar, A.; Smith, L. C.; Seedhouse, C. H.

Abstract

Nucleophosmin is commonly both over-expressed and mutated in acute myeloid leukemia (AML). NPM1 mutations are always heterozygous. In addition, NPM1 has a number of different splice variants with the major variant encoded by exons 1–9 and 11–12 (NPM1.1). Further variants include NPM1.2 which lacks exons 8 and 10 and NPM1.3 which comprises exons 1–10 (and so lacks the region of sequence mutated in AML). In this study we quantified the expression of these three variants in 108 AML patient samples with and without NPM1 mutations and also assessed the level of expression from the wild-type and mutant alleles in variants NPM1.1 and NPM1.2. The results show that NPM1.1 is the most commonly expressed variant, however transcripts from wild-type and mutated alleles do not occur at equal levels, with a significant bias toward the mutated allele. Considering the involvement of mutant nucleophosmin in the progression and maintenance of AML, a bias towards mutated transcripts could have a significant impact on disease maintenance.

Citation

Bailey, G. D., Doolan, L., Baskar, A., Smith, L. C., & Seedhouse, C. H. (2020). Preferential transcription of the mutated allele in NPM1 mutated acute myeloid leukaemia. Scientific Reports, 10, Article 17695. https://doi.org/10.1038/s41598-020-73782-x

• Journal Article Type: Article
• Acceptance Date: Sep 15, 2020
• Online Publication Date: Oct 19, 2020
• Publication Date: Oct 19, 2020
• Deposit Date: Apr 5, 2024
• Publicly Available Date: Apr 16, 2024
• Journal: Scientific Reports
• Electronic ISSN: 2045-2322
• Publisher: Nature Publishing Group
• Peer Reviewed: Peer Reviewed
• Volume: 10
• Article Number: 17695
• DOI: https://doi.org/10.1038/s41598-020-73782-x
• Keywords: Multidisciplinary
• Public URL: https://nottingham-repository.worktribe.com/output/5031392
• Publisher URL: https://www.nature.com/articles/s41598-020-73782-x
• Additional Information: Received: 9 March 2020; Accepted: 15 September 2020; First Online: 19 October 2020; : The authors declare no competing interests.